arrow
Return

The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions

delete2017-08-01
delete27
delete
OA
AI
E
Elise J. Smolders
F
Floor A. C. Berden
C
Clara TMM de Kanter
W
Wietske Kievit
J
Joost P.H. Drenth
D
David M. Burger *
DOI:10.1177/2050640616678151delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
Background: Direct-acting antivirals have improved treatment of chronic hepatitis C virus infection significantly. Direct-acting antivirals inhibit/induce and can also be substrates of drug-metabolising enzymes and transporters. This increases the risk for drug-drug interactions. Objective: The purpose of this study was to predict drug-drug interactions with co-medication used by hepatitis C virus-infected patients. Methods: We assembled a nationwide cohort of hepatitis C patients and collected cross-sectional data on co-medication use. We compiled a list of currently available direct-acting antiviral regimens and cross-checked for potential drug-drug interactions with used co-medication. Results: The cohort included 461 patients of which 77% used co-medication. We identified 260 drugs used as co-medication. Antidepressants (7.4%), proton pump inhibitors (7.1%) and benzodiazepines (7.1%) were most frequently used. Of the patients, 60% were at risk for a clinically relevant drug-drug interaction with at least one of the direct-acting antiviral regimens. Interactions were most common with paritaprevir/ritonavir/ombitasvir/dasabuvir and least interactions were predicted with grazoprevir/elbasvir. Conclusion: Co-medication use is rich in frequency and diversity in chronic hepatitis C patients. The majority of patients are at risk for drug-drug interactions which may affect efficacy or toxicity of direct-acting antivirals or co-medication. The most recently introduced direct-acting antivirals are associated with a lower risk of drug-drug interactions.
Keywords:
Hepatitis C
antiviral therapy
pharmacokinetics
drug-drug interactions
NS5A-inhibitor
NS5B-inhibitor
Protease inhibitor
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

United European Gastroenterology Journal cover
United European Gastroenterology Journal
IF:
6.7
Papers:
1.9K
Citations:
4.9K

Organization

U
Utrecht University
Scholars:
5.9W
Papers: 5.1W
Citations: 5.8W
U
Utrecht University Medical Center
Scholars:
2.1W
Papers: 1.8W
Citations: 30
R
Radboud University Nijmegen
Scholars:
4.4W
Papers: 3.4W
Citations: 5.4W
researcher View more organizations